TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07206498: A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU in Combination With Osimertinib for Patients With Locally Advanced or Metastatic Non- Small Cell Lung Cancer

Sponsor: Wayshine Biopharm, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 48 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,032,100

Rescue Site Savings

+$5,969,040

Unlock Full NCT07206498 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07206498 Rescue Dossier →